May 18th, 2010 The interesting dichotomy of oncology research vs clinical medicine
Over the past few years it has been interesting to watch AACR organise and group it’s sessions by pathways, so you end up with a higgledy piggledy collection of different inhibitors, therapeutics, chemotherapies etc as well as a mix of different tumour types. This works well for the scientist, less so for the clinician who may specialise in only a few cancer types. Meanwhile, at ASCO , everything is organised by cancer track, so if you want to search for data on say, MEK, AKT or c-MET inhibitors for example, then the data is now all over the place and trying to get round and find it all is much more difficult.
